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Variation in the miRNA-433 Binding Site of FGF20
Confers Risk for Parkinson Disease
by Overexpression of a-Synuclein
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William K. Scott,1,2 Eden R. Martin,1,2 and Jeffery M. Vance1,2,*
Parkinson disease (PD) is a common neurodegenerative disorder caused by environmental and genetic factors. We have previously
shown linkage of PD to chromosome 8p. Subsequently, ﬁbroblast growth factor 20 (FGF20) at 8p21.3–22 was identiﬁed as a risk factor
in several association studies. To identify the risk-conferring polymorphism in FGF20, we performed genetic and functional analysis
of single-nucleotide polymorphisms within the gene. In a sample of 729 nuclear families with 1089 affected and 1165 unaffected indi-
viduals, the strongest evidence of association came from rs12720208 in the 30 untranslated region of FGF20. We show in several func-
tional assays that the risk allele for rs12720208 disrupts a binding site for microRNA-433, increasing translation of FGF20 in vitro and
in vivo. In a cell-based system and in PD brains, this increase in translation of FGF20 is correlated with increased a-synuclein expression,
which has previously been shown to cause PD through both overexpression and point mutations. We suggest a novel mechanism of
action for PD risk in which the modulation of the susceptibility gene’s translation by common variations interfere with the regulation
mechanisms of microRNA. We propose this is likely to be a common mechanism of genetic modulation of individual susceptibility to
complex disease.Introduction
The major causes of Parkinson disease (PD [MIM 168600])
are still largely unknown.1,2 The exciting discovery of sev-
eral causative monogenic mutations in PD families can
only explain a very limited number of PD cases.3 In con-
trast, the genetic contribution in approximately 90% of
PD cases is more complex.4 To this end, we have been
actively seeking functionally relevant polymorphic varia-
tions associated with the risk of developing PD.
We previously reported that one such polymorphism,
rs1989754, in the ﬁbroblast growth factor 20 (FGF20 [MIM
605558]) gene, was associated with an increased risk for
PD.5 Several lines of evidence support this association:
(1) FGF20 is located within the chromosome 8 linkage
peak in our previous linkage analysis.6 (2) FGF20 is prefer-
entially expressed in the substantia nigra compared to
other brain regions.7 (3) A recent report showed that
FGF20 has neurotrophic properties and promotes survival
of dopaminergic neurons.8 (4) Clarimon et al. examined
FGF20 in a small case-control dataset and conﬁrmed the
signiﬁcance of the same single-nucleotide polymorphism
(SNP) rs1989754 in a Finnish sample, although it did
not meet stringent Bonferroni correction requirements
when adjusting for multiple comparisons were adjusted
for.9 (5) Maraganore et al. showed association between
rs17515020 within the FGF20 gene and PD in the ﬁrst-
tier analysis (p ¼ 0.03) of their whole-genome association
study of PD but did not consider the SNP in their
second-stage analysis.10 Given these multiple lines of evi-




Affected individuals and family members were collected by the
Duke Center for Human Genetics (DCHG) Morris K. Udall Parkin-
son Disease Research Center of Excellence ascertainment core and
the 13 centers of the Parkinson Disease Genetics Collaboration. A
standard clinical evaluation involves a neurological examination,
including assessment by use of the Uniﬁed Parkinson’s Disease
Rating Scale. Our total dataset includes 729 independent families
with 1089 affected and 1165 unaffected individuals. Unaffected
participants demonstrated no signs of the disease. So that diagnos-
tic consistency could be maintained across participating clinics,
a dually board-certiﬁed neurologist and Ph.D. medical geneticist
(Jeffery M. Vance) reviewed the clinical data for all participants.
Parkin mutation carriers were excluded from this study. All partic-
ipants signed informed consents prior to blood and data collec-
tion. Study protocols and consent forms were approved by institu-
tional review board. All subjects analyzed were white.
DNA Extraction and Genotyping
DNA samples were prepared and stored by the DCHG DNA bank.
Genomic DNAwas extracted fromwhole blood with the PureGene
system (Gentra Systems). Primers and probes were designed with
the Primer Express 2.0 program (Applied Biosystems). The ﬂuores-
cence generated during the PCR ampliﬁcation was detected with
the ABI Prism 7900HT Sequence Detection System and was ana-
lyzed with SDS software (Applied Biosystems). Stringent quality-
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ensured. Internal controls consisted of 24 duplicated individuals
per 384-well plate. Data were stored and managed by the PEDI-
GENE system.
Human FGF20 30 UTR Luciferase Constructs
The Renilla luciferase FGF20 30 untranslated region (UTR) con-
structs were made by a previously reported method.11 The full
length of human FGF20-30 UTR containing both genotypes at
rs12720208 was ampliﬁed with forward primer 50-GATCTCTA
GAAGTGCGATAGTGACATTATGGAAGAGTCAAAC-30 andreverse
primer 50-CATGGATCCGCCAAAACACTGCATGAAAATGTTTAAT
TC-30 from a heterozygous human genomic DNA sample. The
polymerase chain reaction (PCR) product was separated in agarose
gel and extracted, puriﬁed, and cloned with TA cloning Kit (Invi-
trogen, Carlsbad, CA). The inserts containing allele-C and allele-T
were conﬁrmed by sequencing. The 30 UTR of Renilla luciferase in
the vector pRL-SV40 (Promega, Madison, WI) was replaced with
the full-length 30 UTR of FGF20 by restriction enzymes XbaI and
BamHI. Finally, the pRL-FGF20-30 UTR deletion 150–171 construct
was generated with the Quickchange XL site-directed mutagenesis
kit (Stratagene, La Jolla, CA) with forward mutagenic deletion
primer 50-GAGAAAAAAAACCAAAAAAAATTTCACTCTTTATATGT
GGATTAAGTTCCC-30 and a complementary reverse mutagenic
deletion primer, 50-GGGAACTTAATCCACATATAAAGAGTGAAAT
TTTTTTTGGTTTTTTTTCTC-30. The resulting constructs (pRL-FGF20-
30 UTR-C-allele,pRL-FGF20-30 UTR-T-allele,andpRL-FGF20-30UTR-21bp
deletion) were veriﬁed by sequencing.
Luciferase Assay
Neuro2A cells was maintained in minimum essential medium (Ea-
gle) with 0.1% nonessential amino acids, Eagle’s balanced salt so-
lution (BSS), 1 mM sodium pyruvate, and 10% fetal bovine serum
(FBS)at a 37C incubator supplemented with 5% CO2. Cells were
seeded at 3 3 105 cells per well in 24-well plates (BD Biosciences,
Bedford,MA). Sixteenhours after the plating, cells were transfected
by Lipofectamin 2000 according to manufacturer’s suggestion. In
each well, 3.28 fmol pRL-FGF20-30 UTR vector and 0.73 fmol
pGL3 control vector were cotransfected with 0, 0.1, 1, 10, 100
pmol pre-miR-433 accordingly. Five replicates for each group and
the experiment repeated at least three times. After transfection
for 24 hr, cells were harvested by the addition of 100 ml passive lysis
buffer. Renilla luciferase activities in cell lysate weremeasured with
the Dual Luciferase assay system (Promega, Madison, WI) in TD-
20/20 luminometer (Turner Biosystems, Sunnyvale, CA) and
were normalized with the ﬁreﬂy luciferase activities and analyzed
with the t test.
Immunoblot Analysis
At 80% conﬂuences in 6-well plates, human ﬁbroblasts were trans-
fected with 0, 5, and 50 pmol pre-miR-433, respectively, which is
corresponding to 0, 1, and 10 pmol pre-miR-433 when cell cul-
tured in 24-well plates. The ﬁbroblast cells were lysed by radio-im-
munoprecipitation assay (RIPA) buffer (Pierce, Rockford, IL) with
protease inhibitor cocktail (Sigma, St. Louis, MO) by dounce ho-
mogenizer after transfection for 24 hr. SH-SY5Y cells were grown
in minimum essential medium supplemented with 10% fetal bo-
vine serum, 2 mM L-glutamine, 1 mM sodium pyruvate, and 0.1
mMnonessential amino acids. After cells were incubated in starva-
tion medium in which 10% FBS was replaced by 0.1% bovine se-
rum albumin (BSA) for 16 hr, SH-SY5Y cells were stimulated
with recombinant human FGF20 (R&D Systems, Minneapolis,284 The American Journal of Human Genetics 82, 283–289, FebruaMN) at 0, 5, and 50 ng/ml for 24 hr. Total SH-SY5Y cell lysate
was prepared as it was for ﬁbroblast cells. Human brain cortex
was lysed as descried above. Both cell and tissue lysate were clari-
ﬁed by centrifugation. The protein concentration was determined
by 2-D Quant Kit (GE Healthcare, Piscataway, NJ). The cell and tis-
sue lysates were resolved by sodium dodecyl sulfate polyacryl-
amide gel electrophoresis (SDS-PAGE), transferred to nitrocellulose
membranes, and immunoblotted with rat monoclonal anti-FGF20
antibody (R&D Systems, Minneapolis, MN), mouse monoclonal
anti-a-synuclein ntibody (BD Biosciences, Bedford, MA), and
mouse monoclonal anti-b-actin antibody (Sigma, St. Louis, MO).
Proteins were visualized with chemiluminescence (Bio-Rad, Her-
cules, CA). Speciﬁc bands density were quantiﬁed with Fluor-S
MultiImager and analyzed with the t test.
Statistical Analysis
A single affected and unaffected individual were selected at ran-
dom from each family for tests of Hardy-Weinberg disequilibrium.
These tests were conducted with Genetic Data Analysis software,
through the application of a permutation test with 3200 permuta-
tions to estimate each p value (Lewis Lab Software website). Two
measures of linkage disequilibrium (LD), squared correlation coef-
ﬁcient (r2), and Lewontin’s standardized disequilibrium coefﬁcient
(D0) were computed between pairs of SNPs through use of the
Graphical Overview of Linkage Disequilibrium (GOLD) software
package.12 Single-locus association analysis was performed in the
families through use of the pedigree disequilibrium test (PDT).13
We used the PDT sum version of the statistic to compare allele fre-
quencies between affected individuals and their unaffected par-
ents (when available) or siblings within families.14 We used the as-
sociation in the presence of linkage (APL) program as a second test
of association in families.15 APL correctly infers missing parental
genotypes by estimating identity-by-descent parameters for multi-
ple affected siblings even when linkage is present. All tests were
considered statistically signiﬁcant at a ¼ 0.05.
Results
Association Study of Polymorphism in FGF20with PD
To further test the inﬂuence of FGF20 on the risk of PD, we
genotyped eight SNPs within the FGF20 gene in an ex-
panded dataset. Due to the ongoing collection of samples
throughout the duration of the study, the family counts
differ slightly for each SNP genotyped. Our expanded data-
set includes 729 independent families with 1089 affected
and 1165 unaffected individuals. No family that was found
to carry a Parkin mutation was included in this dataset.
Five SNPs presented here were not previously genotyped
in our initial dataset, and four of them are located within
the 30 UTR (Figure 1). No SNP genotyped showed signiﬁ-
cant evidence for deviation from Hardy-Weinberg equilib-
rium. The LD analyses based on r2 revealed strong LD be-
tween SNPs rs1989754 and rs11203822, between SNPs
rs1989754 and rs10888125, and between rs11203822
and rs10888125 in the affected individuals (Table 1).
Values of D0 were large for most SNP pairs, suggesting
that there has been little historic recombination in the re-
gion over time. Levels of LD were similar in the unaffected
set (data not shown).ry 2008
Figure 1. Gene Structure of FGF20
Exons are denoted by blocks; coding regions are shown in gray, and 30 UTRs are shown in white. Locations of SNPs are indicated by arrows.
Underlined SNPs were previously genotyped in the initial study.Two methodologies were utilized for the analysis of ge-
netic association with PD: (1) Results from the PDT13,14
in the expanded dataset were consistent with our previous
report, i.e., single-locus tests demonstrated strong associa-
tion with PD for several SNPs in the overall sample, includ-
ing three 30 UTR SNPs, rs10888125 (p ¼ 0.0009, G allele
positively associated), rs12720208 (p¼ 0.0019, Tallele pos-
itively associated), and rs1721082 (p¼ 0.0029, T allele pos-
itively associated) (Table 2). (2) The APL test15 results were
also signiﬁcant. The strongest association was with the 30
UTR SNP rs12720208 (p ¼ 0.0001) (Table 3).
miR-433 Inhibits FGF20 Translation at SNP
rs12720208
SNP rs12720208 is located 166 bp downstream of the ter-
minating codon of FGF20 and lies within a predicted bind-
ing site for microRNA (miRNA) miR-433. miRNAs are small
noncoding transcripts of approximately 22 nucleotides
that negatively regulate the translation of complementary
messenger RNA (mRNA), usually by binding the 30 UTR. It
is believed that miRNAs play important roles in develop-
ment, cell death, and cell proliferation.16,17
miR-433 is highly expressed in brain but not in heart,
liver, or kidney.18 The allele C of rs12720208 matches the
predicted miR-433 binding domain, whereas the T allele
represents a G:U wobble base pairing (Figures 2A and 2B)
and thus a mismatch. It has been shown that the G:UThe Amwobble base pairing has an inhibitory effect on miRNA-
mediated repression of gene translation.19 Therefore, we
hypothesized that miR-433 would bind tightly to FGF20
mRNA transcripts containing the C allele, negatively regu-
lating FGF20 protein translation. Conversely, the binding
withmRNA transcripts containing the Tallele would be dis-
rupted, allowing ahigher translation of FGF20 into protein.
To test this hypothesis, we replaced the 30 UTRof a Renilla
luciferase reporter gene with the full-length FGF20 30 UTR
containing either the T or the C alleles of rs12720208
(Figure 2C). In transiently transfected Neuro2A cells, the
translation of Renilla luciferase (representing FGF20 pro-
tein) from constructs containing the C allele was dramati-
cally reduced in the presence miR-433 in a concentration-
dependent manner. However, no repression of Renilla
luciferase translation was seen for the T allele construct
when miR-433 was added (Figure 2D). After complete dele-
tion of the miR-433 binding site (21 bp), we observed
signiﬁcantly higher Renilla luciferase translation compared
to the constructs containing either C or Talleles (Figure 2E).
In addition, the larger complete deletion demonstrates
more translation than the smaller deletion, as would be
expected (data not shown). This suggests that indeed,
miR-433 binds and functionally negatively regulates the
protein translation of FGF20, and that this regulation is
disrupted by the presence of the Tallele, presumably affect-
ing miR-433 binding to the FGF20 transcript.Table 1. Measures of Linkage Disequilibrium between FGF20 SNPs
rs1989754 rs11203822 rs1721100 rs12720208 rs1721082 rs10888125 rs17515365 rs17515379
rs1989754 0.96 0.295 0.067 0.218 0.882 0.108 0.004
rs11203822 0.991 0.305 0.075 0.231 0.911 0.114 0.004
rs1721100 0.959 0.983 0.25 0.607 0.334 0.265 0.012
rs12720208 0.899 0.964 0.987 0.334 0.075 0.018 0.046
rs1721082 0.955 0.989 0.904 0.989 0.253 0.515 0.014
rs10888125 0.968 0.993 0.992 0.938 1 0.129 0.003
rs17515365 0.953 0.977 0.841 0.999 1 1 0.001
rs17515379 1 1 1 1 1 1 0.205
r2 values are given in the upper diagonal, and the D0 values are below the diagonal.erican Journal of Human Genetics 82, 283–289, February 2008 285
Table 2. Allele Frequencies and p Value of Single-Locus Association Analysis
Family Triads Discordant Siblings
SNP Allele Parental Transmission Parental Nontransmission (na) Affected Frequency (nb) Unaffected Frequency (nc) PDT p Value
rs1989754C 0.387 0.481 (111) 0.41 (665) 0.432 (902) 0.0029
rs11203822A 0.378 0.49 (103) 0.405 (648) 0.436 (872) 0.0013
rs1721100C 0.324 0.193 (111) 0.3 (670) 0.285 (912) 0.033
rs12720208T 0.1 0.045 (110) 0.105 (720) 0.092 (967) 0.0019
rs1721082T 0.283 0.16 (97) 0.25 (701) 0.221 (935) 0.0029
rs10888125G 0.383 0.495 (103) 0.42 (710) 0.447 (950) 0.0009
rs17515365T 0.155 0.108 (106) 0.14 (705) 0.122 (957) 0.19
rs17515379G 0.01 0 (100) 0.005 (678) 0.004 (930) 0.096
a Number of triads used from nuclear families.
b Number of affected siblings from discordant sibships.
c Number of unaffected siblings from discordant sibships.To further explore the effects of miR-433 on the transla-
tion of FGF20, we used two ﬁbroblast lines, one homozy-
gous for the C allele, the other heterozygous. Immunoblot
analysis showed that miR-433 (1 and 10 pmol) repressed
FGF20 translation in both cell lines, with greater inhibitory
effects found in the ﬁbroblast line homozygous for allele C
(Figure 3A) than in the heterozygous line.
These experiments strongly suggest that miR-433 re-
presses the FGF20 translation in carriers of allele C in vitro.
To explore this in vivo, we compared FGF20 protein levels
in human brain in three subjects with different genotypes.
As a membrane-bound growth factor, both monomer
(about 20 KD) and oligomer (about 100 KD) forms of
FGF20 were observed in the immunoblot assay. Human
brain homozygous for allele T has the highest FGF20 level
of both monomer and oligomer, and brains carrying the C
allele have substantially lower levels of both forms. This is
particularly observed for the oligomer form of FGF20
(Figure 3B). Thus, both in vitro and in vivo studies suggest
that SNP rs12720208 inﬂuences FGF20 translation level by
alternating miR-433 targeting.
Increased FGF20 Leads to a-Synuclein Overexpression
FGF20 belongs to the ﬁbroblast growth factor (FGF) family,
which has at least 22 members. FGFs exert their speciﬁc bi-
ological functions through four different types of ﬁbroblast
growth factor receptors (FGFR1–4).20 By binding to FGFR1,
FGF20 has been reported to promote differentiation of
neural stem cells into tyrosine-hydroxylase-positive cells286 The American Journal of Human Genetics 82, 283–289, Februarand enhance dopaminergic neuron survival.7,21 Interest-
ingly, FGF2, another member in the FGF family that acts
through FGFR1, has been shown to upregulate the expres-
sionofa-synuclein[MIM163890] inculturedratventralmid-
brain dopaminergic neurons.22 Beucase FGF2 and FGF20
both bind to FGFR1, it seemed possible that FGF20 might
also increase a-synuclein levels in dopaminergic neurons.
To test thishypothesis, weused the dopaminergic neuroblas-
toma cell line SH-SY5Y, which has endogenous a-synuclein
expression.23 After incubating SH-SY5Y cells in recombinant
humanFGF20 for 24hr, thea-synucleinprotein levelwas sig-
niﬁcantly increased compared that of to controls (Figures 3C
and 3D). Human brain homozygous for allele T not only has
the highest level of FGF20 translation but also the highest
a-synuclein protein level in three brains with different geno-
types (Figure 3B).
Discussion
Previous studies have shown that mutations of a-synuclein
cause autosomal-dominant PD.24 a-synuclein is the princi-
pal component of ﬁlamentous Lewy bodies, the deﬁning
pathological hallmark of PD.25 Although the exact func-
tion of a-synuclein remains to be understood, pertinent
to this report is that triplication and duplication of the
a-synuclein gene can also cause dominant PD,26–28 and
overexpression of exogenous a-synuclein is involved in
the pathogenesis of PD.29,30 It has been shown that overex-
pression of wild-type a-synuclein reduces the numberTable 3. Allele Frequencies and p Value of Association in the Presence of Linkage
SNP na Observed Transmitted Frequency Expected Transmitted Frequency APL p Value
rs1989754C 689 0.42 0.44 0.02
rs11203822A 684 0.416 0.436 0.003
rs1721100C 693 0.29 0.278 0.02
rs12720208T 729 0.096 0.083 0.0001
rs1721082T 717 0.24 0.223 0.004
rs10888125G 723 0.43 0.452 0.003
rs17515365T 729 0.86 0.863 0.55
rs17515379G 715 0.005 0.003 0.04
a Total nuclear families with at least one affected individual genotyped.y 2008
of tyrosine-hydroxylase-positive neurons differentiated from
neural progenitors and increases the vulnerability of human
dopaminergic neurons to neurotoxic insults, potentially
resulting in neuronal death.31,32 Primates overexpressing
exogenous a-synuclein develop PD-like neuropathological
features, such as a-synuclein-positive inclusions and dys-
trophic neuritis.29
Thus, we suggest that FGF20 increases susceptibility to
PD via chronically elevated levels of a-synuclein in human
brain. During early stages of life, dopaminergic neurons in
midbrain might beneﬁt from FGF20 for proliferation, dif-
ferentiation, and even protection from stress assault. But
at later stages of life, the chronically increased level of
FGF20 can indirectly contribute to dopaminergic neuron
death.
Figure 2. Characterization of miR-433
and Functional Analysis of miR-433 Tar-
geting at the 30 UTR of FGF20 Gene
(A) The predicted binding site for miR-433
at 30 UTR of FGF20 gene. At rs12720208,
allele C base paired with G in Watson-Crick
mode (as shown with a solid line), whereas
allele T wobble base paired with G (as shown
with a dashed line).
(B) The precursor molecule pre-miR-433
proceeds to matured miR-433.
(C) The construct of pRL-SV40-FGF20-30
UTR contains SV40 promoter, renilla lucifer-
ase gene, and full-length 30 UTR of FGF20
gene with different alleles.
(D) The expression of renilla luciferase in
Neuro2A cells transfected by pRL-SV40-
FGF20-30 UTR was measured by relative
luciferase activity. Relative luciferase ac-
tivity stands for renilla luciferase activity
normalized by firefly luciferase activity
which is the internal control. MiR-433 (1–
100 pmol) decreased the expression level
of renilla luciferase significantly in allele
C constructs but not in allele T constructs
(** indicates p < 0.01). Data are mean5
standard error (SE).
(E) The expression of renilla luciferase is
significantly higher in neuro2A cells trans-
fected by pRL-SV40-FGF20-21bp deletion
than the constructs containing either C or
T alleles under miR-433 (10 pmol). Data
are mean5 SE.
miRNAs, as regulatory factors in
large numbers, have great potential
to be important in contributing to
disease risk. A mutation in the 30
UTR of the myostatin gene has been
shown to create a de novo miRNA tar-
get site, allowing miRNA to suppress
the translation of the gene and lead-
ing to the characteristic muscular hy-
pertrophy of Texel sheep.33 Abelson et al. also reported
that rare mutations in the miR-189 targeting site of the
SLITRK1 gene can lead to Tourette syndrome.11 However,
in this report, the variation is not a rare mutation but
a polymorphism, demonstrating the enormous potential
of normal polymorphic variation in miRNA targeting sites
to provide a mechanism for susceptibility genes for a com-
mon complex disease. We predict that this is just the tip of
the iceberg for future research in this area. Because of
elevated FGF20 protein level correlating with enhanced
a-synuclein expression, these results also reinforce the im-
portance of a-synuclein in the pathogenesis of PD. It also
suggests that this mechanism of increasing a-synuclein
expression could be common for many susceptibility
genes in PD.The American Journal of Human Genetics 82, 283–289, February 2008 287
Figure 3. Immunoblot Analysis of Translation Levels of FGF20 and a-Synuclein in Different Genotypic Fibroblasts and Human
Brains
(A) MiR-433 at 1 and 10 pmol significantly suppresses FGF20 protein level in the homozygote allele C and heterozygote at rs12720208
fibroblasts. FGF20 level is much higher in heterozygote cells than in homozygote allele C cells. In the heterozygote at rs12720208 fibro-
blasts, treatment with miR-433 for 24 hr does not change much of monomer form FGF20 (20 KD) but dramatically decreases the oligomer
form of FGF20 (100 KD). The blot was re-probed with b-actin antibody showing the same amount loading.
(B) The human brain of homozygous allele T at rs12720208 has the highest level of both FGF20 and a-synuclein, comparing with the human
brains of homozygous allele C or heterozygous at rs12720208. The blotwas re-probedwithb-actin antibody showing the sameamount loading.
(C) a-synuclein translation amount is dramatically increased in SH-SY5Y cells after incubation with 50ng/ml FGF20 for 24 hr. The blot was
re-probed with b-actin antibody showing the same amount loading.
(D) Quantification of immunoblotted a-synuclein in SH-SY5Y cells treated by FGF20. a-synuclein-band densities were normalized to their
counterpart b-actin-band densities and represented the mean5 SE of three independent experiments (** indicates p < .01).Extending our previous linkage analysis and genetic as-
sociation study, we have successfully identiﬁed the risk-
conferring polymorphism in the FGF20 gene and a likely
biological mechanism for increasing risk of PD. Next steps
will be to explore whether miR-433 and FGF20 will be
potentially useful for PD diagnosis and treatment.
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